Purchase this article with an account.
R. U. Desai, R. Charalel, A. Jain, D. Feliciano, S. R. Sanislo, D. M. Moshfeghi, M. S. Blumenkranz, D. Vollrath; An Analysis of CFH and LOC387715 Genotypes in Age-Related Macular Degeneration Patients: Response to Photodynamic Therapy versus Anti-VEGF Therapy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):230.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We evaluated how the Y402H SNP of complement factor H (CFH) and the A69S SNP of LOC387715 affect exudative AMD response to treatment by photodynamic therapy (PDT) and anti-VEGF therapy (bevacizumab or ranibizumab).
In this retrospective study, a total of 72 patients were genotyped for CFH and LOC387715. Of these, 46 eyes underwent anti-VEGF therapy while 47 eyes underwent PDT. We examined the visual acuity (VA), total macular volume (TMV), and central macular thickness (CMT) pre-treatment and at final follow-up (average 25 months).
The CFH risk C allele, compared to the wildtype T allele, predisposes to 11 Snellen letters VA improvement (p = 0.26) after anti-VEGF therapy and 5 letters improvement (p = 0.57) after PDT. The LOC387715 wildtype G allele, compared to the risk T allele, predisposes to 6 letters improvement (p = 0.48) after anti-VEGF therapy and 5 letters improvement (p = 0.33) after PDT. There was no significant difference in CMT or TMV in patients receiving anti-VEGF therapy or PDT regardless of CFH or LOC387715 genotype.
This PDF is available to Subscribers Only